Levodopa Benserazide Teva (Benserazide Hydrochloride, Levodopa)

Levodopa is a precursor that crosses the blood‑brain barrier and is converted into dopamine, compensating for the loss of dopaminergic neurons. Benserazide inhibits peripheral aromatic L‑amino acid decarboxylase, preventing levodopa from being metabolized outside the brain, thereby increasing its central availability.

The specific dose and dosing schedule are determined by the prescribing physician based on the individual patient's clinical condition, response, and tolerability. Dosage adjustments are made during treatment to achieve optimal symptom control while minimizing side effects.

Safety data for use in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levodopa combined with benserazide is considered the most effective oral therapy for symptomatic control of Parkinson's disease. Compared with dopamine agonists, it often provides stronger motor improvement but may have a higher incidence of motor complications such as dyskinesia. The choice depends on disease stage, patient age, and tolerance.

Store the tablets at room temperature, below 25 °C, in the original packaging. Protect them from moisture and direct sunlight to maintain stability and potency throughout the shelf life.

Levodopa Benserazide Teva is taken orally, usually with a glass of water. It may be administered with or without food, but high‑protein meals can affect absorption, so patients are often advised to take the medication at consistent times relative to meals.

Serious risks include the development of dyskinesia (involuntary movements), hallucinations, severe orthostatic hypotension, and rare neuroleptic malignant syndrome. Patients should be monitored regularly for these events, and any sudden changes in mental status or motor function should be reported promptly.

Patients with known hypersensitivity to levodopa, benserazide, or any excipients should avoid the product. It is also contraindicated in individuals taking non‑selective MAO inhibitors. Caution is advised in patients with severe cardiac disease, uncontrolled hypertension, or a history of neuroleptic malignant syndrome.